Cargando…
Direct-acting antiviral treatments display excellent outcomes even in older HCV-infected patients at increased risk of fibrosis
BACKGROUND: This study compared the efficacy and tolerability of available direct-acting antiviral (DAA) regimens between individuals aged 60 years and older and younger patients in a real-life setting. Specifically, we aimed to provide evidence of the efficacy and safety of DAAs in the treatment of...
Autores principales: | Xia, Huan, Zhang, Yaping, Zaongo, Silvere D., Liang, Jing, Gong, Xiaowen, Hu, Yue, Ma, Ping, Wang, Fengmei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184475/ https://www.ncbi.nlm.nih.gov/pubmed/34164481 http://dx.doi.org/10.21037/atm-21-1297 |
Ejemplares similares
-
Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China
por: Xia, Huan, et al.
Publicado: (2020) -
HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016) -
Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents
por: Abu-Freha, Naim, et al.
Publicado: (2023) -
HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019) -
The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)